Changing Faces: Board appointments, November and December 2025
As 2025 came to a close, we also saw a modest number of Board appointments, on both advisory and governance Boards.
Protein degrader biotech appoints new chair, advisor. TRIMTECH Therapeutics, a UK biotech creating novel, highly selective, small molecule targeted protein degraders to combat neurodegenerative and inflammatory diseases, appointed Alison Lawton as Chair of the Board. Her most recent position was as CEO of Kaleido Biosciences. She had also held COO roles at Aura Biosciences and X4 Pharmaceuticals. TRIMTECH also appointed Dr Mike Hutton to its Scientific Advisory Board. Hutton has held major neuroscience leadership roles at Eli Lilly, MSD, and the Mayo Clinic.
Austrian cancer biotech assembles leadership board. VALANX Biotech, a Vienna biotech focused on innovative approaches to cancer treatment including site-specific protein conjugation, appointed four members to its Board of Directors: Dr Michael Boehler, who helped launch the first mRNA COVID vaccine at BioNTech; Dr Alexander Schwartz, a former McKinsey Consultant; Dr Urs Spitz, a scientist, investor, and serial entrepreneur; and Ingo S. Nagler, a seasoned biotech executive and investor.
Laboratory services leader adds pharma veteran to board. Lab services giant LabCorp appointed Novartis US President Victor Bultó to its Board of Directors. A 25-year healthcare executive, Bultó joined the Board as of 1st December to support LabCorp’s strategic growth priorities.
Biotechnology companies strengthen boards with industry leaders. Several biotechs announced prominent Board appointments.
- Blue Cell Therapeutics, a Danish biotech developing long lasting allogeneic "off-the-shelf" human mesenchymal stem cell (MSC) therapies, appointed Dr Miguel Forte to its Board of Directors. He currently serves as president and Chair of the Board of Directors at the International Society for Cell & Gene Therapy.
- Life Biosciences, a Boston biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of ageing, named Dr David Guyer to its Board of Directors. The co-founder and former CEO of Eyetech Pharmaceuticals, he currently serves as president and CEO of EyeBio and as a venture partner at SV Health Investors.
- Strand Therapeutics, a Boston biotech developing next generation programmable mRNA therapies, appointed Jeb Keiper to its Board of Directors. The former CEO of Nimbus therapeutics also spent nearly a decade at GSK.
TechBio company builds out advisory board. Concr, a London-based techbio company that uses astrophysics-derived methods to predict which cancer treatments will work for individual patients, made two appointments to its Advisory Board. Dr Judith Reece spent over two decades leading digital and data transformation in pharmaceutical R&D, including as executive director of corporate strategy at AstraZeneca and VP of digital development at GSK. Jay Campbell led venture investments for the Cancer Research Institute and served as chief business officer of publicly listed Immutep Ltd, having previously executed over $13.4 billion in strategic and financing transactions as a life sciences investment banker.
Kidney disease biotech establishes clinical advisory board. Fibrocor Therapeutics, a Canadian and Belgian outfit developing first-in-class therapies that target kidney diseases at their roots by blocking fibroblast activation and excessive collagen deposition, established a Clinical Advisory Board comprising Rachel Lennon, Daniel Gale, Bertrand Knebelmann, and Dr Alessia Fornoni. The line up emphasises expertise in basement membrane biology, genetic kidney diseases, and glomerular disorders.
Stay posted for more Board appointments in 2026 and remember, you can send your own hires to editorial@pharmaphorum.com for inclusion in this column.
